drugset
Drugs / Young Tumor Infiltrating Lymphocytes (TIL)
last change May 2017 re-read 3 minutes ago

Young Tumor Infiltrating Lymphocytes (TIL)

Cell therapy

Developed for
metastatic melanoma · uveal melanoma
Investigated by
National Cancer Institute (NCI)

Trials 2

today NCT01814046 · Ph 2 NCT01468818 · Ph 2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01814046 Mar 2013 → May 2017 uveal melanoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT01468818 Sep 2011 → Aug 2013 metastatic melanoma, skin cancer National Cancer Institute (NCI) Terminated No outcome recorded Stop: Enrollment

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Young Tumor Infiltrating Lymphocytes (TIL) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01468818 ↗
1

NCT01814046 ↗
Modality Cell therapy “adoptive transfer of young tumor infiltrating lymphocytes” NCT01468818 ↗
Route Intravenous “cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.)” NCT01468818 ↗